FR2651677B1 - Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. - Google Patents

Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.

Info

Publication number
FR2651677B1
FR2651677B1 FR909011142A FR9011142A FR2651677B1 FR 2651677 B1 FR2651677 B1 FR 2651677B1 FR 909011142 A FR909011142 A FR 909011142A FR 9011142 A FR9011142 A FR 9011142A FR 2651677 B1 FR2651677 B1 FR 2651677B1
Authority
FR
France
Prior art keywords
salmeterol
fluticasone propionate
pharmaceutical composition
composition based
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR909011142A
Other languages
English (en)
French (fr)
Other versions
FR2651677A1 (fr
Inventor
Palmer James Barry Douglas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2651677(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2651677A1 publication Critical patent/FR2651677A1/fr
Application granted granted Critical
Publication of FR2651677B1 publication Critical patent/FR2651677B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FR909011142A 1989-09-08 1990-09-07 Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. Expired - Lifetime FR2651677B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (2)

Publication Number Publication Date
FR2651677A1 FR2651677A1 (fr) 1991-03-15
FR2651677B1 true FR2651677B1 (fr) 1993-08-06

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
FR909011142A Expired - Lifetime FR2651677B1 (fr) 1989-09-08 1990-09-07 Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.

Country Status (20)

Country Link
EP (1) EP0416951B1 (nl)
JP (1) JP3042867B2 (nl)
AT (1) ATE99941T1 (nl)
BE (1) BE1003053A3 (nl)
CA (1) CA2024916C (nl)
CH (1) CH680983C9 (nl)
DE (2) DE69005951T2 (nl)
DK (1) DK0416951T3 (nl)
ES (1) ES2062392T3 (nl)
FR (1) FR2651677B1 (nl)
HK (1) HK18695A (nl)
HU (1) HU211272A9 (nl)
IE (1) IE65535B1 (nl)
IL (1) IL95590A (nl)
IT (1) IT1241996B (nl)
LU (1) LU90392I2 (nl)
NL (1) NL990012I2 (nl)
NZ (1) NZ235221A (nl)
PH (1) PH27594A (nl)
SG (1) SG166294G (nl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
HU0004452D0 (nl) * 1991-12-18 2001-01-29 Astra Ab
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
EP1283036B2 (de) 1998-11-13 2020-01-01 Jagotec AG Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ES2274803T3 (es) 1999-09-11 2007-06-01 Glaxo Group Limited Formulacion farmaceutica de propionato de fluticasona.
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
EP2067784A3 (en) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
MXPA03009940A (es) 2001-04-30 2004-01-29 Glaxo Group Ltd DERIVADOS ANTI-INFLAMATORIOS DE 17. BETA-CARBOTIOATO ESTER DE ANDROSTANO CON UN GRUPO DE ESTER CICLICO EN LA POSICIoN 17.ALFA.
EP1425001B1 (en) 2001-09-14 2008-12-17 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1483231A1 (de) * 2002-03-04 2004-12-08 Boehringer Ingelheim Pharma GmbH & Co.KG Neue salmeterol-zimtsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PL375819A1 (en) 2002-12-12 2005-12-12 Altana Pharma Ag Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
CA2534934A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
AP2006003734A0 (en) * 2004-03-12 2006-10-31 Cipla Ltd Inhalation formulation
NZ552523A (en) 2004-07-16 2010-11-26 Almirall Sa Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
WO2008077623A1 (en) 2006-12-22 2008-07-03 Laboratorios Almirall, S.A. Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101748892B1 (ko) 2009-05-29 2017-06-19 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
AU2014228414B2 (en) 2013-03-15 2018-09-13 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
NL990012I1 (nl) 1999-07-01
DE69005951T2 (de) 1994-05-26
IL95590A0 (en) 1991-09-16
EP0416951A1 (en) 1991-03-13
CA2024916A1 (en) 1991-03-09
DK0416951T3 (da) 1994-02-14
CH680983C1 (nl) 2008-06-25
IL95590A (en) 1996-06-18
IE65535B1 (en) 1995-11-01
JPH03167120A (ja) 1991-07-19
ATE99941T1 (de) 1994-01-15
HK18695A (en) 1995-02-17
HU211272A9 (en) 1995-11-28
SG166294G (en) 1995-06-16
NL990012I2 (nl) 1999-09-01
PH27594A (en) 1993-08-31
CH680983C9 (nl) 2008-08-15
IE903256A1 (en) 1991-03-13
DE69005951D1 (de) 1994-02-24
LU90392I2 (fr) 1999-06-28
FR2651677A1 (fr) 1991-03-15
IT1241996B (it) 1994-02-02
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
DE19975040I2 (de) 2006-07-13
CH680983A5 (nl) 1992-12-31
IT9048260A0 (it) 1990-09-07
JP3042867B2 (ja) 2000-05-22
NZ235221A (en) 1992-11-25
CA2024916C (en) 2002-07-09
EP0416951B1 (en) 1994-01-12
BE1003053A3 (fr) 1991-11-05

Similar Documents

Publication Publication Date Title
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
FR2651678B1 (fr) Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
CA2123909A1 (en) New combination of formoterol and budesonide
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
ZA96779B (en) Calcitonin salmon analogues their preparation medicinal use and use as analytical agents
MY111155A (en) Medicaments

Legal Events

Date Code Title Description
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; NAT. REGISTRATION NO/DATE: NL 25847 20000626; FIRST REGISTRATION: SE - 14 591 19980907

Spc suppl protection certif: 00C0027

Filing date: 20001002

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 2000C0027, 20001002

CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: 2000C0027, 20001002, EXPIRES: 20130907

LIMR Limitation of claims
SPCC Change of owner's name or address for a supplementary protection certificate

Owner name: GLAXO GROUP LIMITED

Free format text: PRODUCT NAME: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; NAT. REGISTRATION NO/DATE: NL 25847 20000626; FIRST REGISTRATION: 14 591 19980907

Spc suppl protection certif: 00C0027

Filing date: 20001002